Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells

Neuroscience Letters

Volumn 432, Issue 2, 2008, Pages 146-150

  Nakaso, Kazuhiro ^a   Ito, Satoru ^a   Nakashima, Kenji ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Akt PKB; Caffeine; Coffee; Neuroprotection; Phosphatidyl inositol 3 kinase (PI3K)

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CAFFEINE; CASPASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETINOIC ACID; ROTENONE; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PARKINSON DISEASE; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIPARKINSON AGENTS; APOPTOSIS; CAFFEINE; CELL LINE, TUMOR; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NEUROBLASTOMA; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PARKINSON DISEASE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 39149085654     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.12.034     Document Type: Article

References (23)

1. Alvira D., Yeste-Velasco M., Folch J., Casadesus G., Smith M.A., Pallas M., and Camins A. Neuroprotective effects of caffeine against complex-I inhibition-induced apoptosis are mediated by inhibition of the Atm/p53/E2F-1 path in cerebeller granule neurons. J. Neurosci. Res. 85 (2007) 3079-3088
2. Ascherio A., Chen H., Schwarzschild M.A., Zhang S.M., Colditz G.A., and Speizer F.E. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 60 (2003) 790-795
3. Ascherio A., Weisskopf M.G., O'Reilly E.J., McCullough M.L., Calle E.E., Rodriguez C., and Thun M.J. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am. J. Epidemiol. 160 (2004) 977-984
4. Chade A.R., Kasten M., and Tanner C.M. Nongenetic causes of Parkinson's disease. J. Neural Transm. Suppl. 70 (2006) 147-151
5. Dall'Igna O.P., Fett P., Gomes N.W., Souza D.O., Cunha R.A., and Lara D.R. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp. Neurol. 203 (2007) 241-245
6. Evans A.H., Lawrence A.D., Potts J., MacGregor L., Katzenschlager R., Shaw K., Zijlmans J., and Lees A.J. Relationship between impulsive sensation seeking trails, smoking, alcohol, and caffeine intake, and Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 77 (2006) 317-321
7. Hall E.D., Andrus P.K., Oostveen J.A., Althaus J.S., and VonVoigtlander P.F. Neuroprotective effects of dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced nigrostriatal neurons. Brain Res. 742 (1996) 80-88
8. Hancock D.B., Martin E.R., Stajich J.M., Jewett R., Stacy M.A., Scott B.L., Vance J.M., and Scott W.K. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson's disease. Arch. Neurol. 64 (2007) 576-580
9. Hernan M.A., Logroscino G., and Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66 (2006) 1097-1099
10. Hernan M.A., Takkouche B., Caamano-Isorna F., and Gastal-otero J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52 (2002) 276-284
11. Kalda A., Yu L., Oztas E., and Chen J.F. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal model s of Parkinson's disease. J. Neurol. Sci. 248 (2006) 9-15
12. Nakaso K., Nakamura C., Sato H., Imamura K., Takeshima T., and Nakashima K. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem. Biophys. Res. Commun. 339 (2006) 915-922
13. Ongini E., Adami M., Ferri C., and Bertorelli R. Adenosine A2A receptors and neuroprotection. Ann. N. Y. Acad. Sci. 825 (1997) 30-48
14. Ragonese P., Salemi G., Morgante L., Aridon P., Epifanio A., Buffa D., Scoppa F., and Savettieri G. A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson's disease. Neuroepidemiology 546 (2003) 297-304
15. Ross G.W., Abbott R.D., Petrovitch H., Morens D.M., Grandinetti A., Tung K.H., Tanner C.M., Masaki K.H., Blanchette P.L., Curb J.D., Popper J.S., and White L.R. Association of coffee and caffeine intake with the risk of Parkinson's disease. JAMA 283 (2000) 2674-2679
16. Schapira A.H., and Olanow C.W. Neuroprotection in Parkinson's disease: mysteries, myths and misconceptions. JAMA 291 (2004) 358-364
17. Schwarzschild M.A., Xu K., Oztas E., Petzer J.P., Castagnoli K., Castagnoli Jr. N., and Chen J.F. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal model of Parkinson's disease. Neurology 61 (2003) S55-S61
18. Seidler A., Hellenbrand W., Robra B.P., Vieregge P., Nischan P., Joerg J., Oertel W.H., Ulm G., and Schneider E. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46 (1996) 1275-1284
19. Ueki A., and Otsuka M. Life style risk of Parkinson's disease: association between decreased water intake and constipation. J. Neurol. 251 (2004) 18-23
20. Wirdefeldt K., Gatz M., Pawitan Y., and Pedersen N.L. Risk and protective factors for Parkinson's disease: a study in Swedish twins. Ann. Neurol. 57 (2005) 27-33
21. Xu K., Xu Y.H., Chen J.F., and Schwarzschild M.A. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci. Lett. 322 (2002) 13-16
22. Xu K., Yu Y., Brown-Jermyn D., Chen J.F., Ascherio A., and Dluzen D.E. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model pf Parkinson's disease. J. Neurosci. 26 (2006) 535-541
23. Youdim M.B., Bar Am O., Yogev-Falach M., Weinreb O., Maruyama W., Naoi M., and Amit T. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability translation. J. Neurosci. Res. 79 (2005) 172-179